Although not a component of the IFN-γ pathway, B2M was included because of its role in MHC-I presentation and anti-tumor immunity, but it was not a hit in our initial IFN-γ survival screens as B2M variants should not have an effect on cell proliferation in vitro. The gene discussed is B2M; the disease is neoplasm.